NCT02883647 Therapeutic Effects and Long-term Follow-up After Ending Nucleos(t)Ide Analogs Therapy in Chronic Hepatitis b
| NCT ID | NCT02883647 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Third Affiliated Hospital, Sun Yat-Sen University |
| Condition | Chronic Hepatitis b |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2014-01-01 |
| Primary Completion | 2024-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2014-01-01 with a primary completion date of 2024-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study is to observe the therapeutic effects and long-term follow-up after ending anti-HBV therapy with nucleos(t)ide analogs in patients with chronic hepatitis b.
Eligibility Criteria
Inclusion Criteria: 1. Patients received anti-HBV therapy with nucleos(t)ide analogs. 2. Last anti-HBV therapy should continue for at least 2 years. 3. For HBeAg positive patients, HBV DNA should keep negative for at least 1 year after HBeAg seroconversion before the therapy ending; for HBeAg negative patients, HBV DNA should keep negative for at least 2 years before the therapy ending. Exclusion Criteria: 1. Liver cirrhosis, HCC; 2. Patients with other factors causing active liver diseases; 3. Pregnancy or lactation; 4. Patients with HIV infection or congenital immune deficiency diseases; 5. Patients with severe diabetes, autoimmune diseases, other important organ dysfunctions and other serious complications.
Contact & Investigator
Liang Peng, Doctor
PRINCIPAL INVESTIGATOR
Third Affiliated Hospital, Sun Yat-Sen University
Frequently Asked Questions
Who can join the NCT02883647 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Chronic Hepatitis b. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02883647 currently recruiting?
Yes, NCT02883647 is actively recruiting participants. Contact the research team at xwx1983@163.com for enrollment information.
Where is the NCT02883647 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT02883647 clinical trial?
NCT02883647 is sponsored by Third Affiliated Hospital, Sun Yat-Sen University. The principal investigator is Liang Peng, Doctor at Third Affiliated Hospital, Sun Yat-Sen University. The trial plans to enroll 100 participants.